PURPOSE: Dose calculation during optimization of volumetric modulated arc therapy (VMAT) is necessarily simplified to keep computation time manageably low; however the approximations used in the scatter dose calculation lead to discrepancy with more accurate dose calculation following optimization. The purpose of this study is to develop a dose correction strategy in optimization that can minimize the disagreement. METHODS: VMAT delivery is modeled using a number of static equispaced beams. Dose correction factors (C(ij)) are associated with each beam i and point j inside the region of interest. C(ij) is calculated as the ratio of dose obtained from the full scatter dose calculation over that from the partial scatter dose calculation in optimization. VMAT optimization algorithm is a multiple resolution approach. The dose correction factors are calculated at the beginning of each resolution and applied as multiplicative corrections to the partial scatter dose during optimization. Clinical cases for brain, prostate, paraspinal, and esophagus are utilized to evaluate the method. Treatment plans created with and without the correction scheme are normalized such that the complication rates of organs at risk (OARs) are comparable. The resulting planning target volume (PTV) mean doses are used to compare plan quality. RESULTS: The difference between the dose calculated at the end of optimization and at the end of the final forward dose calculation is reduced from 7% and 5% for the PTV and OAR mean doses without correction to approximately 1% with correction. Applying dose correction during optimization saves planners 2-4 h in average in treatment planning, and has a positive impact on plan quality, evidenced by a noticeably higher PTV mean dose: 2.1%, 2.4%, 0.5%, and 9.3% of the corresponding prescription dose in the brain, esophagus, prostate, and paraspinal cases, respectively. CONCLUSIONS: When dose correction is applied during optimization, dose discrepancies between optimization and full dose calculation are reduced. Integrating dose correction in VMAT optimization allows planners to adjust the optimization constraints more easily and confidently during optimization and has the potential to improve plan quality.
PURPOSE: Dose calculation during optimization of volumetric modulated arc therapy (VMAT) is necessarily simplified to keep computation time manageably low; however the approximations used in the scatter dose calculation lead to discrepancy with more accurate dose calculation following optimization. The purpose of this study is to develop a dose correction strategy in optimization that can minimize the disagreement. METHODS: VMAT delivery is modeled using a number of static equispaced beams. Dose correction factors (C(ij)) are associated with each beam i and point j inside the region of interest. C(ij) is calculated as the ratio of dose obtained from the full scatter dose calculation over that from the partial scatter dose calculation in optimization. VMAT optimization algorithm is a multiple resolution approach. The dose correction factors are calculated at the beginning of each resolution and applied as multiplicative corrections to the partial scatter dose during optimization. Clinical cases for brain, prostate, paraspinal, and esophagus are utilized to evaluate the method. Treatment plans created with and without the correction scheme are normalized such that the complication rates of organs at risk (OARs) are comparable. The resulting planning target volume (PTV) mean doses are used to compare plan quality. RESULTS: The difference between the dose calculated at the end of optimization and at the end of the final forward dose calculation is reduced from 7% and 5% for the PTV and OAR mean doses without correction to approximately 1% with correction. Applying dose correction during optimization saves planners 2-4 h in average in treatment planning, and has a positive impact on plan quality, evidenced by a noticeably higher PTV mean dose: 2.1%, 2.4%, 0.5%, and 9.3% of the corresponding prescription dose in the brain, esophagus, prostate, and paraspinal cases, respectively. CONCLUSIONS: When dose correction is applied during optimization, dose discrepancies between optimization and full dose calculation are reduced. Integrating dose correction in VMAT optimization allows planners to adjust the optimization constraints more easily and confidently during optimization and has the potential to improve plan quality.
Authors: Cedric X Yu; X Allen Li; Lijun Ma; Dongjun Chen; Shahid Naqvi; David Shepard; Mehrdad Sarfaraz; Timothy W Holmes; Mohan Suntharalingam; Carl M Mansfield Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: Daliang Cao; Timothy W Holmes; Muhammad K N Afghan; David M Shepard Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-01 Impact factor: 7.038